RxDoctor Payments Data

Lori Brown

Family · Midland, TXNPI 1023520830

Payments from drug & device makers

$1,333in general payments, 2019–2025

Across 68 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$420
  • Lilly USA, LLC$164
  • Boehringer Ingelheim$157
  • Abbott$124
  • Astellas Pharma US Inc$106
  • Sanofi-aventis U.S. LLC$76
  • plus $287 from 9 others

What the payments were for

  • Food & beverage$1,333100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,333 in reported general payments places this provider in the 70th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$22,005
Medicare patients
108
Services billed
646

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin56$54,273
FarxigaDapagliflozin Propanediol38$53,890
EliquisApixaban45$48,784
MounjaroTirzepatide31$40,185
TrulicityDulaglutide30$33,596
TradjentaLinagliptin18$17,297
JanuviaSitagliptin Phosphate18$15,520
LinzessLinaclotide17$14,330
GlyxambiEmpagliflozin/Linagliptin12$12,269
JanumetSitagliptin Phos/Metformin Hcl26$11,841
Lantus SolostarInsulin Glargine,hum.Rec.Anlog73$9,691
InvokanaCanagliflozin11$6,021
SymbicortBudesonide/Formoterol Fumarate12$2,610
CombiganBrimonidine Tartrate/Timolol12$2,407
Levemir FlexpenInsulin Detemir14$2,224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Glyxambi$157$83,83986 claims
Lilly USA, LLCMounjaro, Trulicity$164$73,78161 claims
AstraZenecaFarxiga, Symbicort$420$56,50050 claims
PfizerEliquis$57$48,78445 claims
AbbVieLinzess, Combigan$16$16,73729 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 15,456 family providers in Texas.

Other family in Midland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →